Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure − A Single Centre Case Series and Call for an International Registry

An improvement in life expectancy in patients suffering from adult congenital heart disease (ACHD) has corresponded with a rise in heart failure incidence within this group. An area that has not been addressed in ACHD heart failure guidelines has been the use of combined inhibition of angiotensin receptor-neprolysin pathways. This case series sought to demonstrate tolerability and 6-month outcome measures of sacubitril/valsartan use in ACHD patients with a severely impaired systemic ventricle.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Original Article Source Type: research